Claim Ledger
77% answered
Did management answer the analysts?
12 analyst questions audited, 1 evaded or deflected.
View Claim Ledger →
Biocon Limited — Q4 FY26
Biocon delivered a strong Q4 FY26, with adjusted revenue growth of 10% YoY and EBITDA up 29% YoY to ₹1,073 crore, driven by favorable mix and operating leverage in biosimilars.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Biocon delivered a strong Q4 FY26, with adjusted revenue growth of 10% YoY and EBITDA up 29% YoY to ₹1,073 crore, driven by favorable mix and operating leverage in biosimilars. The biosimilars segment grew 12% YoY with margins expanding to 26%, while generics (ex-lenalidomide) grew 13%. The integration of biosimilars and generics was completed in under 100 days, strengthening the balance sheet. Management highlighted that the heavy investment phase is behind, with focus shifting to execution and margin expansion. Key launches in FY27 include aflibercept (Yesafili) and insulin aspart (Kirsty), expected to ramp up in H2. Risks include potential pricing erosion in the US biosimilar market and competitive pressure from Chinese entrants in insulin.
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Pricing erosion in US biosimilars
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Biosimilar Revenue (Q4)
₹2,756 Cr
+12% YoY
Driven by advanced markets; sequential growth of 12% from Q3.
Insulin Franchise Revenue (FY26)
$300M+
+50% YoY
Crossed $300M; includes clargine, aspart, human insulin.
Adalimumab Revenue (FY26)
$250M+
+25% YoY
Global biosimilar adalimumab franchise.
Bevacizumab Market Share (US)
~25%
Flat YoY
Steady market share in US oncology medical benefit space.
What Changed vs Last Quarter
NEW
Biosimilar revenue growth of 16% in FY26 on like-to-like basis
Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27.
NEW
EBITDA margin expansion of ~200bps in FY26 on like-to-like basis
Margins improved to 22% for FY26; management expects further operating leverage as new products ramp up.
NEW
Net debt reduction to ~$1.1B from $1.5B in March 2025
Free cash flow will be prioritized for deleveraging; interest cost savings of ~₹75 Cr per quarter expected.
NEW
Aflibercept (Yesafili) launch in US in H2 FY27
Settlement with originator allows entry; management expects meaningful revenue contribution from H2.
DROPPED
Annualized interest savings of ~₹300 crore from FY27
Management expects annualized interest cost savings of approximately ₹300 crore starting FY27, following the retirement of structured debt.
DROPPED
Biosimilar EBITDA margin to be in mid-20s for full year FY26
Management reiterated that biosimilar EBITDA margin for the full year FY26 will be in the mid-20s, despite Q3 margin of 28%.
DROPPED
Capex to moderate to <$225 million and further decline
Group capex has moderated from ~$275 million to less than $225 million, and will decline further as Malaysia insulin capacity buildup completes.
DROPPED
Insulin drug product capacity to double in FY27
The Malaysia insulin drug product capacity expansion is expected to go commercial in FY27, doubling current capacity.
NEW RISK
Pricing erosion in US biosimilars
Competitive pressure and ASP declines in medical benefit products could impact margins.
NEW RISK
Chinese competition in insulin
Recent Chinese approvals in insulin could disrupt pricing and market share.
NEW RISK
CRDMO revenue growth slowdown
Syngene's FY26 revenue grew only 3% YoY due to a large client impact; recovery uncertain.
NEW RISK
Execution risk on new product launches
Ramp-up of aspart and aflibercept depends on capacity qualification and market adoption.
RISK GONE
CRDMO segment weakness due to single customer issue
CRDMO revenue declined 3% YoY due to challenges with one customer, and management acknowledged the pressure will take time to ease.
RISK GONE
Regulatory uncertainty for GLP-1 generics in Canada
Health Canada has not approved any generic GLP-1, including liraglutide, due to unclear regulatory requirements, delaying semaglutide launch.
RISK GONE
Potential erosion of legacy biosimilar revenues
Management noted that while new launches drive growth, legacy products may face erosion, which could offset some gains.
RISK GONE
Competitive pressure from innovator GLP-1 formulations
Novo Nordisk's potential launch of a different formulation (e.g., oral) could impact generic GLP-1 market dynamics.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q1 FY26, Q2 FY25, Q2 FY26, Q3 FY25, Q4 FY25
Market share and ASPs are inversely proportional; increased competition could erode pricing and margins.
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25
Yesintek (biosimilar to Stelara) will launch in the US in February 2025, with a global rollout including Europe.
Mentioned in Q1 FY26, Q4 FY25
Adalimumab in the U.S. remains a work in progress with pricing pressure and dominance of private labelers (Sandoz/CVS); market share gains uncertain.
Mentioned in Q1 FY26, Q2 FY26
Generics R&D spend is expected to be in the 8-10% range of segment revenue.
Mentioned in Q1 FY25, Q2 FY25
Management expects a transition to accelerated growth in H2, driven by Syngene returning to growth, maintained biosimilars momentum, and generics recovery from new launches.
Fast read
Guidance and risk preview
Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27.
Competitive pressure and ASP declines in medical benefit products could impact margins.
View Risks →